Protara Therapeutics Inc (TARA) — Cash Flow-to-Debt Ratio
Protara Therapeutics Inc (TARA) has a Cash Flow-to-Debt Ratio of -1.30x as of December 2025, meaning its operating cash flow of $-16.95 Million could theoretically repay -1% of its total liabilities ($13.06 Million) in one year. See TARA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Protara Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Protara Therapeutics Inc across 14 annual periods. Also explore TARA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Protara Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Protara Therapeutics Inc. For market capitalisation and broader financial context, see TARA market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.32x | $-56.37 Million | $13.06 Million | ▼ -72.6% |
| 2024 | -2.50x | $-35.81 Million | $14.32 Million | ▲ +29.2% |
| 2023 | -3.53x | $-37.56 Million | $10.63 Million | ▼ -49.6% |
| 2022 | -2.36x | $-26.46 Million | $11.21 Million | ▲ +26.9% |
| 2021 | -3.23x | $-34.50 Million | $10.68 Million | ▲ +46.0% |
| 2020 | -5.98x | $-23.41 Million | $3.91 Million | ▲ +77.7% |
| 2019 | -26.84x | $-15.65 Million | $583.00K | ▼ -255.5% |
| 2018 | -7.55x | $-23.23 Million | $3.08 Million | ▼ -212.0% |
| 2017 | -2.42x | $-22.35 Million | $9.24 Million | ▲ +48.1% |
| 2016 | -4.66x | $-23.69 Million | $5.08 Million | ▼ -9.7% |
| 2015 | -4.25x | $-17.57 Million | $4.13 Million | ▲ +0.5% |
| 2014 | -4.27x | $-9.99 Million | $2.34 Million | ▼ -522.7% |
| 2013 | -0.69x | $-6.70 Million | $9.77 Million | ▲ +65.4% |
| 2012 | -1.98x | $-8.23 Million | $4.15 Million | — |